Beam Therapeutics Inc. Common Stock
$24.67
$1.57 (+6.80%)
$24.05Day Range$25.50
Key Statistics
Market Cap
$2.55B
Shares Outstanding
103.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 6, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$24.28
Day High
$25.50
Day Low
$24.05
Volume
2.43M
VWAP
$24.78
Prev Close
$23.10
Transactions
--
Acc. Volume
--
About Beam Therapeutics Inc. Common Stock
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836540 employees26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139857-327-8775IPO Feb 6, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001745999
- Composite FIGI
- BBG00KXC8646
- Share Class FIGI
- BBG00KXC8655
- Ticker Root
- BEAM
- SIC Code
- 2836
About Beam Therapeutics Inc. Common Stock (BEAM) Stock
Beam Therapeutics Inc. Common Stock (BEAM) closed the 2026-09-17 session at $24.67, up 6.80% versus the previous close (+1.57). The stock opened at $24.28 and traded between $24.05 and $25.50 during that session. Session trading volume was 2.4M shares. The volume-weighted average price (VWAP) is $24.78.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Beam Therapeutics Inc. Common Stock has a market capitalization of $2.55 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. BEAM is listed on the XNAS exchange. The company employs approximately 540 people. Beam Therapeutics Inc. Common Stock is headquartered in CAMBRIDGE, MA. The recorded listing date is 2020-02-06.
On this page you can find market BEAM stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.